KORSANA BIOSCIENCES

Korsana Biosciences Overview

November 2026

Nasdaq: KRSA

Disclaimers

This presentation has been prepared by Korsana Biosciences, Inc. ("Korsana" or the "Company"), is provided as of the date hereof, is subject to change without notice, and is for information purposes only. It does not purport to contain all of the information necessary to evaluate an investment in the Company and is not a recommendation that any person make such an investment. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the Company's securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Forward-Looking Statements. Certain information set forth in or made orally during this presentation contains "forward-looking statements" within the meaning of the U.S. federal securities laws, including Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, statements regarding: the Company's business strategy and its ability to develop potentially best-in-class therapies for neurodegenerative disorders, including a shuttled anti-Aβ therapy offering meaningful improvements over trontinemab; the efficacy, safety profile, dosing regimen, convenience, half-life and tolerability of KRSA-028, including its subcutaneous formulation, dosing volume and projected human pharmacokinetics; the expected timing of CTN and IND filings, healthy volunteer PK and CSF data, and interim clinical proof of concept data for KRSA-028; the expected timing of unveiling additional pipeline programs; estimated market sizes and the anticipated growth of the Alzheimer's therapeutics market and the eligible patient population; and the Company's expectation that its existing cash resources will fund operations into 2029. Words such as "may," "will," "could," "anticipate," "believe," "expect," "intend," "potential," "estimate," "plan" and similar expressions or their negatives may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements are neither historical facts nor assurances of future performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially, including: regulatory feedback, including disagreement by regulatory authorities with our clinical trial design or interpretation of data; risks related to early stage pre-clinical and clinical development; risks related to our patent portfolio and to intellectual property licensed from third parties, including Paragon Therapeutics; our reliance on third parties for the development, manufacture and supply of our product candidates, and conduct of pre-clinical studies and clinical trials; the possibility that we use our capital resources sooner than expected and that additional financing may not be available on acceptable terms, or at all; macroeconomic conditions and changes in law, tariffs, sanctions and export or import controls; adverse events or disappointing results in clinical trials of third parties, including competitors targeting similar mechanisms of action or indications; and the other risks described in the Company's filings with the Securities and Exchange Commission, including the risk factors set forth on Forms 10-K, 10-Q, and 8-K as well as risk factors associated with companies, such as Korsana, that operate in the biopharma industry. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by applicable securities laws, the Company undertakes no obligation to update them.

Market and Industry Data. Certain information contained herein is based on studies, publications and other data obtained from third-party sources, as well as the Company's own internal estimates and research. The Company believes such sources to be reliable as of the date hereof but has not independently verified them and makes no representation as to their accuracy or completeness, and its internal analyses have not been verified by any independent source. This presentation contains comparisons of data across separate, non-head-to-head studies. No head-to-head study has been conducted comparing KRSA-028 to any other product candidate or approved agent, including trontinemab. Differences exist between study designs and patient populations, and caution should be exercised in drawing conclusions from cross-study comparisons. Data relating to third-party products have been extracted via digitization of published figures and represent approximate values.

Investigational Product Candidates. KRSA-028 and the Company's other product candidates are investigational and have not been approved for any use by the U.S. Food and Drug Administration or any other regulatory authority. No conclusions can or should be drawn regarding their safety or effectiveness.

Trademarks. This presentation contains trademarks of the Company, including THETA™, and of third parties, which are the property of their respective owners. Such marks may appear without the ® or ™ symbols; no relationship with, or endorsement by, their respective owners is intended or implied.

KORSANA BIOSCIENCES

KORSANA BIOSCIENCES

Building next-generation therapeutics for neurodegenerative diseases, starting with Alzheimer's

1. **Founded by Fairmount and Venrock** and led by an experienced team with a track record of building and advancing innovative biotechnology companies
2. **Lead program KRSA-028** is a next-generation CNS shuttled anti-amyloid antibody designed to deliver a potentially best-in-class therapeutic profile for Alzheimer's disease
3. **Purpose-built** to combine clinically validated biology and technologies with proprietary engineering to reduce risk and drive differentiation
4. **Strong financial position with ~$456M[1] in cash**, providing runway into 2029 and through multiple clinical milestones

[1]Cash and cash equivalents as of September 30, 2026.



CONFIDENTIAL

Korsana is founded on four key beliefs



Alzheimer's is a vast and de-risked opportunity

*For the first time, there is a **validated, disease-modifying target for Alzheimer's** – but first-generation amyloid beta therapies leave **substantial room for improvement**.*



Shuttling is the best way to improve existing agents

*Transferrin receptor (TfR)-based shuttling is a de-risked modality to **increase brain penetration**; Roche's **trontinemab has provided proof-of-principle** in Alzheimer's disease.*



Korsana has the potential best-in-class approach

*Lead program KRSA-028 is potentially **superior to trontinemab,** and we are **advancing multiple next-generation programs**.*



Korsana has a rapid path to value creation

*KRSA-028 development can be **highly de-risked in Phase 1,** as amyloid clearance is proven to translate to clinical benefit – creating **significant early value inflection**.*

KORSANA BIOSCIENCES


KORSANA BIOSCIENCES




Alzheimer’s is a vast and de-risked opportunity

Alzheimer's is a devastating neurological disorder with significant unmet need and a rapidly growing patient population

The number of Americans with Alzheimer's is **projected to nearly double** by 2050






Alzheimer's disease is a **massive and growing unmet need**,
with associated long-term healthcare costs projected to be **>$1T by 2050**.

Sources: 2024 Alzheimer's Association (Alzheimer's Dement); 2025 Alzheimer's Association (Alzheimer's Dement).
Cost of care includes CMS payments, out of pocket costs, and other costs for health care and long-term care for people with Alzheimer's or other dementias.


KORSANA BIOSCIENCES

Despite clinical progress and approvals, today's anti-Aβ therapies leave significant room for improvement

Approved therapies only demonstrate **~30% slowing of disease progression** at 18 months…



…and carry **black box warnings for ARIA risk,** affecting **~15-25%** of treated patients




Although these therapies are disease-modifying, patients **still experience progression**, with potential for **new therapies to deliver superior efficacy and safety**.

Notes: CDR-SB: Clinical Dementia Rating – Sum of Boxes, the functional Phase 3 endpoint for Alzheimer's trials. Data from some time points was digitized from original publications. Donanemab data based on mixed models for repeated measures (MMRM). ARIA: amyloid-related imaging abnormality; ARIA-E: edema and effusion; ARIA-H: microhemorrhage.
Sources: 2023 Sims (JAMA); 2023 van Dyck (NEJM)

KORSANA BIOSCIENCES

Approved therapies are also highly inconvenient, with onerous IV dosing and MRI monitoring on label




Notes: BL: baseline. Patients can be taken off Kisunla if they are "amyloid negative" at physician's discretion.
Sources: Leqembi FDA Label; Kisunla FDA Label

KORSANA BIOSCIENCES

First-gen therapies have laid out the roadmap for success: amyloid reduction predicts slowing of cognitive decline

Cognitive Decline
CDR-SB adjusted mean difference from placebo



Plaque Clearance
Amyloid PET adjusted mean difference from placebo (centiloids)
Greater reduction is better

> *"The Agency has found… that **reduction of brain Aβ plaque on PET is reasonably likely to predict clinical benefit in Alzheimer's disease**."*
> – Donanemab FDA Review

> *"It is reasonable to conclude that **treatment that is targeted at reducing amyloid plaque**, and that successfully accomplishes that reduction, **has the potential to convey clinical benefit**."*
> – Lecanemab FDA Review

The field now has a **well-trodden path to regulatory success** for anti-amyloid beta therapies, with risk **discharged early in clinical development** with a validated biomarker.


Notes: Bubble size indicates sample size at baseline. CDR-SB: Clinical Dementia Rating Scale-Sum of Boxes, the functional Phase 3 endpoint for Alzheimer's trials. CDR-SB is a dementia severity scale ranging from 0 to 18 with higher scores indicating greater impairment.
Sources: 2023 Boxer (Cell).

KORSANA BIOSCIENCES

KORSANA BIOSCIENCES

Shuttling is the best way to improve existing agents

Shuttling approaches actively ferry large molecules across the blood-brain barrier (BBB), fundamentally changing CNS penetration




Notes: Figure made in BioRender. Adapted from 2024 Kulic (CTAD Presentation); 2022 Edavettal (Med).


KORSANA BIOSCIENCES

Roche's trontinemab, the first shuttled anti-Aβ antibody, has shown a significant efficacy improvement over first-gen gantenerumab…

Trontinemab shows **~8x increased CSF exposure** over gantenerumab in humans…




… and most trontinemab-treated Alzheimer's patients **reached "amyloid-negative" status** by W28



Notes: CSF: cerebrospinal fluid. Roche CSF data digitized from AD/PD presentation and represents Roche's own cross-trial comparison, with trontinemab CSF to plasma ratio from single-dose IV study compared to historical data from a prior gantenerumab SAD trial. Amyloid reduction is a cross-trial comparison. Gantenerumab dosing titrates up to 510 mg Q2W maintenance dosing. 0 CL anchored on "high certainty" young, healthy controls & 100 CL anchored on typical AD patients. A threshold of 24.1 CL discriminates sparse from moderate plaque presence and is generally viewed as the cutoff for classifying patients as "amyloid negative." Sources: 2021 Kulic (AD/PD Presentation); 2023 Bateman (NEJM); 2025 Kulic (CTAD Presentation), 2025 Klein (AAIC Presentation).

KORSANA BIOSCIENCES

… and greatly reduces ARIA, the critical safety signal for this class of therapies



Notes: Comparisons are across trials with different patient populations and trial designs, including study duration. No head-head-to-head comparison studies have been conducted. Trontinemab values include placebo patients (patients were randomized 4:1); N otherwise refers to patients on drug. ARIA: amyloid-related imaging abnormality; ARIA-E: edema and effusion; ARIA-H: microhemorrhage.


Sources: 2023 Bateman (NEJM); 2022 van Dyck (NEJM); 2023 Sims (JAMA) 2025 Kulic (AAIC Presentation)

KORSANA BIOSCIENCES

Trontinemab validates the shuttled Aβ approach, with remaining opportunities to improve the overall product profile

Efficacy


Mean amyloid plaque reductions from baseline



Rapid, robust plaque clearance establishes a high bar, with **opportunity to match or improve upon** this benchmark [1]

Safety

Mean hemoglobin changes from baseline



Trontinemab's full effector function leads to reticulocyte destruction, with **decreased hemoglobin** and **10-20% rates of clinical anemia** observed in Phase 2 [1]

Dosing & Tolerability

Incidence of infusion related reactions

Treatment emergent AEs: infusion-related reactions (IRRs)

IRRs are common and generally mild-to-moderate in severity

1.8 mg/kg or placebo	**50%** N=38 of 76
3.6 mg/kg or placebo	**44%** N=33 of 75

Trontinemab requires **IV dosing** and is associated with a **high rate of infusion-related reactions,** even with steroid pre-medication [2]

Sources: [1] Adapted from 2025 Kulic (CTAD, AAIC presentations). [2] Adapted from 2025 Kulic (CTAD Presentation). Parts 1 and 2 of study, pooled with placebo (4:1 randomization). Steroid pre-medication for all doses was implemented starting in Part 2 of the study. Per Kulic 2025 AAIC slides, steroid pre-medication was used in a majority of infusions. Roche has presented data showing most infusions did not lead to IRR, but table above shows the percent of patients in Part 1 + 2 who experienced an IRR at some point during the study.

KORSANA BIOSCIENCES

KORSANA BIOSCIENCES

Korsana has the potential best-in-class approach

Korsana's goal is to achieve a best-in-class shuttled Aβ therapy, offering meaningful improvements over trontinemab

Key Value Drivers for KRSA-028



FAST, ROBUST AMYLOID REDUCTIONS

- Efficacy on par or greater than trontinemab



DIFFERENTIATED SAFETY PROFILE

- Minimal ARIA risk, avoid hematologic AEs
- Avoid hypersensitivity and infusion reactions



CONVENIENT, PATIENT-FRIENDLY DOSING

- Low-volume subcutaneous autoinjector for infrequent dosing (Q4W or less)
- No need for corticosteroid premedication

KORSANA BIOSCIENCES


KRSA-028 is a next-gen, potentially best-in-class shuttled anti-Aβ

Pyroglutamate-Aβ targeted backbone

- Targets the Aβ epitope associated with the **greatest amyloid plaque clearance** in clinical studies
- **Preferential, high-affinity binding to amyloid plaques**

Proprietary Fc engineering

- Leverages clinically validated **half-life extension** to reduce dosing frequency
- Selective **effector function modulation** designed to maintain amyloid plaque clearance by phagocytosis while **reducing complement activation and risk of anemia**



Subcutaneous formulation

- Expected to be **efficacious at lower dose** than first-generation shuttled therapies
- Optimized for **low volume monthly SC dosing,** with high concentration and low viscosity

Validated shuttle targeting


- Novel sequence leverages proven TfR1 target and epitope, designed to **improve brain penetration** and **reduce ARIA risk**

Enabled by **Therapeutic Targeting (THETA™)**

- Precision-engineered for **optimized half-life, distribution, and effector function**
- Proprietary combination of clinically validated technologies offers **de-risked differentiation**

KORSANA BIOSCIENCES

Targeting the plaque-specific pyroglu-Aβ epitope has been shown to deliver promising clinical efficacy in Phase 3 trials



Antibody	*Aβ epitope / species targeted*
Donanemab	**3pE (pyroglutamate) / plaques**
Aducanumab	Oligomers, protofibrils, fibrils, plaques
Lecanemab	Oligomers, protofibrils, fibrils
Gantenerumab	Oligomers, protofibrils, fibrils, plaques
Crenezumab	Monomers, oligomers, fibrils, plaques *Fc-null – no phagocytosis*
Solanezumab	Primarily monomers

Note: Remternetug (not shown) is Lilly's follow-on program to donanemab and also targets pyroglu-Aβ epitope; Phase 3 trial is ongoing

Notes: Bubble size indicates sample size at baseline. Image adapted from 2023 Boxer (Cell).
Other sources: KISUNLA FDA review; 2012 DeMattos (Neuron); ADUHELM FDA review; LEQEMBI FDA Review; 2023 Soderberg (Neurotherapeutics); 2016 Ultsch (Sci Rep); 2023 Sperling (New Engl J Med); 2024 Soderberg (Sci Reports); company press releases.

KORSANA BIOSCIENCES

KRSA-028 targets plaque-selective pyroglu-Aβ to maximize plaque clearance through phagocytosis


KRSA-028 Aβ backbone:

- Same **plaque-selective epitope** as donanemab and remternetug
- **High Aβ affinity,** K_D = 17 nM
- **Potent phagocytosis (ADCP),** EC_{50} = 0.21 nM

Donanemab *(Kisunla) is the only approved Alzheimer's treatment that targets 3pE-Aβ, but it features high immunogenicity and ARIA.*

Remternetug *is Lilly's follow-on program to donanemab with reduced immunogenicity, currently in Ph3 as a subcutaneous treatment.*

KRSA-028 exhibits potent pyroglu-Aβ phagocytosis




Representative plot shows mean ± SD, n=3 replicates. 20 µg/mL pHrodo-red labeled 3pE-Aβ fibrils incubated 24 hrs with activated monocytes (U937 cells)


KORSANA BIOSCIENCES

KRSA-028 has a longer half-life than trontinemab and avoids reticulocyte depletion in NHPs

KRSA-028 has >2.5x half-life in NHPs compared to trontinemab



KRSA-028 avoids reticulocyte depletion in NHPs




All compounds were dosed single dose in non-human primates (NHP, n=3/group), equimolar to 20 mg/kg trontinemab
Reticulocyte data normalized to reticulocyte count at day -7 and presented as mean ± SEM
Non-shuttled mAb (remternetug), with less immunogenic potential than donanemab, chosen as negative control.


KORSANA BIOSCIENCES

KRSA-028 shows improved brain penetration in mouse and NHP

KRSA-028 demonstrates increased brain penetration in hTfR1/hFcRn mouse model




KRSA-028 shows >6x brain penetration in NHPs compared to trontinemab



Data are mean ± SD. Values below 5 ng/mg (mice) and 1.25 ng/mg (NHP) are estimates as concentrations are below lower limit of quantitation. All compounds were dosed as a single dose (n=3/group). Mice and NHPs were dosed KRSA-028 equimolar to 10 mg/kg trontinemab. Non-shuttled mAb (remternetug) chosen as negative control and dosed at 20 mg/kg. NHP brain PK is an average of concentrations (separately analyzed) from frontal cortex, caudate, putamen, temporal cortex, hippocampus, and cerebellum. Data only collected for first two timepoints for non-shuttled mAb.

KORSANA BIOSCIENCES

KRSA-028 is expected to match trontinemab Phase 3 IV exposure with low volume SC, compatible with autoinjector



Note: 250 mg trontinemab corresponds to the Ph3 dose of 3.6 mg/kg for average weight of 70 kg; model assumes 50% bioavailability

- PK model suggests that KRSA-028 will match trontinemab Phase 3 exposure with a **monthly SC volume of 1-2 mL**
- Initial KRSA-028 formulation achieved **150mg/mL with low viscosity**, compatible with autoinjector development
- **High stability** in human serum and in NHP
- Robust early formulation stress-test results **de-risk SC development pathway**
- Korsana plans to **initiate clinical development with SC dosing**

KORSANA BIOSCIENCES

We believe KRSA-028 preclinical data accelerate & de-risk development

Precision engineered for a differentiated therapeutic profile

- **Novel Aβ and TfR1 binding sequences** retain key features of clinically validated molecules
- **High affinity pyroglu-Aβ binding** and clearance via ADCP leverage best-proven mechanism of efficacy
- **TfR1 binding matches trontinemab epitope with similar affinity,** leveraging the best-proven mechanism of brain distribution
- **Clinically validated Fc modifications** add half-life extension and effector function modulation to enable a lower dose and reduce anemia risk
- **Early formulation work supports high concentration, low viscosity** to enable low-volume SC
- **Composition of matter** patent applications filed


KORSANA BIOSCIENCES

KORSANA BIOSCIENCES


Korsana has a rapid path to value creation

PET imaging in early clinical development provides rapid proof of concept and dose-ranging for amyloid plaque clearing

Trontinemab Phase 1/2: Robust dose-response by Day 50



Remternetug Phase 1: Robust dose-response by Day 85



We believe **KRSA-028 amyloid PET** data – **achievable in a Phase 1/1b trial** – should provide high confidence in **predicting Phase 3 CDR-SB**, the endpoint for full approval.

Notes: Remternetug data from Ph1 LAKB study (IV). Remternetug phase 3 regimen is administered subcutaneously; dose not disclosed.
Source: 2025 Kulic (CTAD Presentation); 2023 Jin (AD/PD Presentation).

KORSANA BIOSCIENCES

A confluence of scientific innovations and market dynamics are driving Alzheimer's treatment to a major inflection point

Despite a slower than expected launch, sales of Aβ therapies are accelerating

- **Improved dose regimens** (SC, dose titration)
- **Blood-based biomarkers are gaining traction**
- **Increasing footprint of global approvals**
- **Future entrants (e.g., trontinemab) will further grow market**

Sales expected to approach $1.5B in 2026; $5B+ in 2030

Upcoming catalysts in presymptomatic AD may lead to rapid market expansion

- **Donanemab TRAILBLAZER-ALZ 3** (~2027)
- **Lecanemab AHEAD 3-45** (~2028)
- **Remternetug TRAILRUNNER-ALZ 3** (~2029)
- **Trontinemab PrevenTRON** (~2032)

Data could greatly expand eligible patient pool

The future of Alzheimer's treatment will center on a **prevention-based paradigm**, where patients are **diagnosed before symptom onset** and given a **safe, convenient Aβ plaque-clearing therapy.**

Sources: Biogen SEC filings; Lilly SEC filings; VisibleAlpha

KRSA-028 Phase 1/2 trial: designed to rapidly deliver potentially differentiating data

Trial design: Single Ascending Dose in healthy volunteers, with integrated Multiple Ascending Dose in Alzheimer's disease patients, and expansion cohorts designed to enable Phase 3



Data Mid-27:
Safety, PK, and CNS distribution


Key Data YE'27-1Q'28:
Plaque clearance by PET imaging

Intended to rapidly enable
Phase 3 Program

Note: Trial design pending regulatory approval

KORSANA BIOSCIENCES

Korsana is well-funded through multiple clinical milestones



Move quickly to dose ranging & expansion cohorts, intended to support ***rapid initiation of pivotal trials***

Strong cash position of ~$456M[1] supports KRSA-028 Phase 3 readiness as well as pipeline expansion, with runway into 2029

[1]Cash and cash equivalents as of September 30, 2026.

KORSANA BIOSCIENCES



Raising Expectations

Building best-in-class therapeutics to reduce the burden of neurodegenerative diseases because patients and caregivers **deserve better**

1

Vast, de-risked opportunity

Alzheimer's is a massive, growing unmet need with amyloid clearance clinically and regulatorily validated as a disease-modifying approach.

2

KRSA-028: designed to be best-in-class

Next-generation shuttled anti-amyloid designed to build on clinically validated plaque-clearing biology with improved safety and convenience, including low-volume, monthly subcutaneous dosing.

3

Rapid and capital-efficient path to value

Healthy volunteer PK and CSF data expected in mid-2027, followed by Alzheimer's patient amyloid PET and biomarker PoC data by YE'27–1Q'28.

4

Well-capitalized, with a proven team

~$456M[1] cash funds operations into 2029, led by seasoned leadership and board, and backed by top-tier investors.

[1]Cash and cash equivalents as of September 30, 2026.

KORSANA BIOSCIENCES

Shares outstanding

As of September 30, 2026		Number of Shares[1]
COMMON STOCK	Shares outstanding	45.5M
COMMON STOCK EQUIVALENTS	Series B preferred	4.1M
	Pre-funded warrants	5.4M
COMMON STOCK AND COMMON STOCK EQUIVALENTS	**Total shares outstanding[2]**	**55.1M**

1. Shown on an as-converted-to-common basis; 2. Excludes common stock equivalents issuable under the company's stock incentive plans and warrants issuable to Parasa. Details may not sum to totals due to rounding.

KORSANA BIOSCIENCES

KORSANA BIOSCIENCES

Thank you